Review of the current literature regarding cardiac adverse events following COVID-19 vaccination

Çınar, Tufan; Hayıroçlu, Mert Ilker; Çiçek, Vedat; Selçuk, Murat; Yavuz, Samet; Orhan, Ahmet Lütfüllah

doi:10.1590/1806-9282.20210940

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this way, the patient benefited from avoiding dual antiplatelet therapy after PCI. Previous reviews in the literature, and also different case reports, have recorded some AMI occurrences following COVID-19 mRNA vaccination [7] , [12] . However, AMI occurred in all those cases following the first or second dose of COVID-19 vaccine.…”

Section: Discussionmentioning

confidence: 96%

“…However, rare severe side effects have also been reported, including cardiac adverse events, most often acute myocarditis and pericarditis [6] . In contrast, it appears that only 5 cases with acute myocardial infarction (AMI) have been reported [7] and most of these case reports referred to the relationship between vaccination and AMI occurrence as being uncertain [8] , [9] , [10] . Nonetheless, it is important to acknowledge that mechanisms responsible for thrombotic events in COVID-19 are still not fully understood [11] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine

Kawamura

Yoshimachi

Nanao

et al. 2023

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine

Kawamura

Yoshimachi

Nanao

et al. 2023

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Cardiopulmonary complications following COVID-19 vaccinations: a systematic review and meta-analysis

Bnar J. Hama Amin,

Dana H. Mohammed Saeed,

Hadi Mohammed Abdullah

et al. 2023

Barw Medical Journal

View full text Add to dashboard Cite

Clinical trials of COVID-19 vaccines were insufficient to detect uncommon adverse outcomes that are crucial for risk-benefit analyses and informing clinical practice post-vaccination. As a result, the detection of infrequent adverse events has become a global research priority. The current study aims to estimate the rate of cardiopulmonary complications associated with COVID-19 vaccination.Two databases and one search engine were explored to identify English language-related studies published up to January 2023.The literature search turned up a total of 3974 relevant studies. Of them, 37 articles matched the inclusion criteria. The mean age of patients was 26.4 years, and about 77% of them were male. The most common reported consequence was inflammatory heart disease (myo-peri-cariditis) (77%), followed by pulmonary embolism (17%), and myocardial infarction (5%). The majority of complications were reported following mRNA COVID-19 vaccinations, particularly following the administration of the second dose. Pfizer has a slightly higher risk of cardiac complications following vaccination (4.1 per 100000 persons) than Moderna (3.7 per 100,000 persons). Although cardiopulmonary complications associated with COVID-19 vaccinations are uncommon, they can be life-threatening. Therefore, more large-scale observational studies and review articles of those studies are strongly recommended.

show abstract

Review of the current literature regarding cardiac adverse events following COVID-19 vaccination

Cited by 2 publications

References 17 publications

A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine

A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine

Cardiopulmonary complications following COVID-19 vaccinations: a systematic review and meta-analysis

Contact Info

Product

Resources

About